Cannabidiol
The most researched non-psychoactive cannabinoid — with an FDA-approved medication and thousands of clinical studies.
CBD is the second most abundant cannabinoid in cannabis and the dominant compound in hemp. Non-psychoactive and well-tolerated, it has demonstrated efficacy for epilepsy, anxiety, inflammation, and pain — with an FDA-approved pharmaceutical (Epidiolex) for rare seizure disorders.
Cannabidiol (CBD) is the most extensively researched non-psychoactive cannabinoid and has emerged as one of the most significant therapeutic compounds discovered in the 20th century. Unlike THC, CBD does not produce intoxication and is generally well-tolerated across a wide dose range.
CBD's mechanism of action is complex and multifaceted. Rather than binding directly to CB1 or CB2 receptors with high affinity, CBD acts as a negative allosteric modulator of CB1 receptors (reducing THC's psychoactive effects), an agonist at serotonin 5-HT1A receptors (anxiolytic effects), a TRPV1 channel activator (pain and inflammation), and an inhibitor of adenosine reuptake (anti-inflammatory). This multi-target pharmacology explains its broad therapeutic profile.
The landmark approval of Epidiolex (pharmaceutical-grade CBD) by the FDA in 2018 for Dravet syndrome and Lennox-Gastaut syndrome — two severe, treatment-resistant epilepsy syndromes — marked a turning point for cannabis medicine. It was the first plant-derived cannabis medicine approved by the FDA and provided definitive clinical evidence of CBD's anticonvulsant properties.
Product quality is the defining challenge in the CBD market. The 2019 FDA analysis found that 26% of CBD products contained significantly less CBD than labeled, and 21% contained more. Batch-level Certificates of Analysis from ISO 17025 accredited laboratories are the only reliable way to verify CBD content and confirm THC levels.
Full spectrum CBD — which preserves the complete cannabinoid and terpene profile including trace THC (≤0.3%) — is increasingly preferred over CBD isolate for most therapeutic applications. The entourage effect produces superior outcomes in multiple studies. Broad spectrum CBD (THC non-detect) offers a middle ground for those requiring verified zero THC.
Federally Legal
Hemp-derived CBD (≤0.3% THC) is federally legal in the US under the 2018 Farm Bill. Cannabis-derived CBD remains federally illegal but is legal in states with medical/recreational cannabis programs.
Federally Legal
Hemp-derived CBD (≤0.3% THC) is federally legal in the US under the 2018 Farm Bill. Cannabis-derived CBD remains federally illegal but is legal in states with medical/recreational cannabis programs.
Our editorial team has tested hundreds of CBD-containing products. These brands consistently deliver the highest quality formulations, most transparent lab testing, and best therapeutic outcomes.
World-leading scientist formulation. Standardized full spectrum profiles, not just a CBD count. Pioneered the cannabis topical liniment spray.
Liniment spray is the most effective topical staff have tested.
Best For
Same world-leading scientist as CBDWellness. Verified THC non-detect on every batch by ISO 17025 accredited lab — trusted by military, athletes, and law enforcement.
The only broad spectrum brand staff trust for drug-tested professionals.
Best For
Editorial Disclosure: These brands are selected by our editorial team based on independent staff testing, lab result analysis, and 7 years of annual awards data. We do not accept payment for editorial placement. See our Annual Awards methodology for full details.